Herceptin,”promising new immunotherapy for metastatic breast canceralpha-HER2 antibody binds receptor, blocks EGF binding & increases HER2 endocytosismonoclonal antibody that recognizes that the epitope is going to be the extracellular domain of Her2; going to prefererntially target the tumor cells b/c they are going to have the highest concentration of Her2 on the plasma membraneblocking antibody (increase endocytosis–> not only prevents binding of ligand
but will bind AP2 in clathrin and make it endocytose)*reducing levels of those receptors selectively from the tumor cell*will stop additional cells from being generated b/c turning off the signaling pathway””agile”” therapyalso going to receive taxol (or derivative of)–>that’s what’s going to kill the tumor cellsHerceptin* more specific for tumor cell; taxol will have all sorts of side effects”